{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T01:17:05Z","timestamp":1791335825535,"version":"4.3.1"},"reference-count":51,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"5","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO Precision Oncology"],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec><jats:title>PURPOSE<\/jats:title><jats:p> Leptomeningeal disease (LMD) in epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma is associated with a poor prognosis and limited treatment options. Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor with confirmed CNS penetration. This study reports on outcomes of patients with EGFR-mutated non\u2013small-cell lung cancer who developed LMD and were subsequently treated with osimertinib. <\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p> We identified patients treated with osimertinib 80 mg PO daily under a compassionate access scheme across nine tertiary Australian institutes between July 2017 and July 2020. Patient demographics, tumor characteristics, and treatment history were collected. Median overall survival, median progression-free survival, disease control rates (DCR), and overall response rates (ORR) were assessed. Kaplan-Meier analysis was performed and descriptive statistics were used. <\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p> Thirty-nine patients were analyzed of which 74% were female. Exon 19 deletions (49%) and L858R point mutations (41%) were the most common EGFR mutations. Forty-nine percentage of patients were Eastern Cooperative Oncology Group 1. The median duration of osimertinib therapy was 6 months. The extracranial DCR and ORR were 60% and 54%, and the intracranial DCR and ORR were 68% and 53%, respectively. Median overall survival was 10.5 months (95% CI, 8.17 to 15.05 months). <\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p> There are limited treatment options for LMD in EGFR-positive lung cancer, and osimertinib at a dose of 80 mg daily is an active therapeutic option for these patients. <\/jats:p><\/jats:sec>","DOI":"10.1200\/po.20.00464","type":"journal-article","created":{"date-parts":[[2021,3,26]],"date-time":"2021-03-26T19:59:14Z","timestamp":1616788754000},"page":"561-568","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":9,"title":["Standard-Dose Osimertinib in EGFR-Mutated Non\u2013Small-Cell Lung Adenocarcinoma With Leptomeningeal Disease"],"prefix":"10.1200","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5969-1577","authenticated-orcid":false,"given":"Luke S.","family":"McLean","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasek","family":"Faisal","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Ballarat Health Services, Ballarat, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sagun","family":"Parakh","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Austin Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven C.","family":"Kao","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia"},{"name":"Sydney Medical School, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig R.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Prince of Wales Hospital, Sydney, New South Wales, Australia"},{"name":"Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9972-8119","authenticated-orcid":false,"given":"Melvin T.","family":"Chin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Prince of Wales Hospital, Sydney, New South Wales, Australia"},{"name":"Prince of Wales Clinical School, University of New South Wales, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Voskoboynik","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Alfred Health, Melbourne, Victoria, Australia"},{"name":"Central Clinical School, Monash University, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malinda J.","family":"Itchins","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Royal North Shore Hospital, St Leonards, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9872-997X","authenticated-orcid":false,"given":"Ross R.","family":"Jennens","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Department of Medical Oncology, Epworth Health, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam R.","family":"Broad","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Andrew Love Cancer Centre, Geelong, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa A.","family":"Morris","sequence":"additional","affiliation":[{"name":"Southern Blood and Cancer Service, Dunedin, New Zealand"},{"name":"Department of Medicine, University of Otago, Dunedin, New Zealand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3059-5730","authenticated-orcid":false,"given":"Benjamin J.","family":"Solomon","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia"},{"name":"Sir Peter MacCallum Department of Oncology, University of Melbourne, Parkville, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djw279"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.44.2806"},{"key":"b3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30146-2"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30649-1"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1214886"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.03.007"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1406766"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.2147\/OTT.S171665"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904554"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1038\/nature13385"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-04-2818"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv276"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0810699"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-1588"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2017.03.010"},{"key":"b17","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21033"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713137"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3182773f21"},{"key":"b22","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2015.05.023"},{"key":"b23","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.029"},{"key":"b24","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000669"},{"key":"b25","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-018-0581-2"},{"key":"b26","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.05.007"},{"key":"b27","doi-asserted-by":"publisher","DOI":"10.21037\/cco.2019.02.02"},{"key":"b28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.018"},{"key":"b29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.113"},{"key":"b30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00026-1"},{"key":"b31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"b32","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(06)70443-4"},{"key":"b33","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-018-0581-2"},{"key":"b34","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/S0140-6736(16)30825-X","volume":"388","author":"Mulvenna P","year":"2016","journal-title":"Lancet"},{"key":"b35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.017"},{"key":"b36","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.21037\/tlcr-20-579","volume":"9","author":"McLean L","year":"2020","journal-title":"Transl Lung Cancer Res"},{"key":"b37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.032"},{"key":"b38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-2246"},{"key":"b39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002003"},{"key":"b40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00457"},{"key":"b41","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2017.394"},{"key":"b42","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0399"},{"key":"b43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.77.9363"},{"key":"b44","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181e2138b"},{"key":"b45","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000380"},{"key":"b46","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.07.010"},{"key":"b47","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1929-4"},{"key":"b48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2018.08.882"},{"key":"b49","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-012-1929-4"},{"key":"b50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.11.268"},{"key":"b51","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nor121"}],"container-title":["JCO Precision Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/PO.20.00464","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,29]],"date-time":"2022-05-29T08:23:23Z","timestamp":1653812603000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/PO.20.00464"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":51,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["10.1200\/PO.20.00464"],"URL":"https:\/\/doi.org\/10.1200\/po.20.00464","relation":{},"ISSN":["2473-4284"],"issn-type":[{"value":"2473-4284","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"2020-11-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-04","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-22","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-03-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}